Discover open access scientific publications

Search, annotate, share and cite publications

Publications by S. Maclachlan

P2.01-58 Demographics, Clinical Characteristics and Treatment Sequencing in Stage III Unresectable NSCLC Patients: A Cancerlinq Cohort

Journal of Thoracic Oncology

English

Related publications

P1.15-27 Patient Characteristics, Treatment Patterns and Survival for Unresectable Stage III NSCLC in Ontario, Canada

Journal of Thoracic Oncology

English

P2.01-91 Treatment Patterns in Patients With Stage IIIB-IV NSCLC in Clinical Practice: Retrospective Analysis of a UK Trust Database

Journal of Thoracic Oncology

English

P1.01-88 Osimertinib Maintenance After Definitive Chemoradiation in Patients With Unresectable EGFRm-Positive Stage III NSCLC (LAURA)

Journal of Thoracic Oncology

English

MA05.02 PACIFIC Subgroup Analysis: Pneumonitis in Stage III, Unresectable NSCLC Patients Treated With Durvalumab vs. Placebo After CRT

Journal of Thoracic Oncology

English

OA01.07 Updated Results of a Phase II Trial of Concurrent Chemoradiation With Consolidation Pembrolizumab in Patients With Unresectable Stage III NSCLC

Journal of Thoracic Oncology

English

P1.17-04 Curative Intent Treatment for Stage III NSCLC in England

Journal of Thoracic Oncology

English

Demographics, Clinical Disease Characteristics, and Quality of Life in a Large Cohort of Psoriasis Patients With and Without Psoriatic Arthritis

Clinical, Cosmetic and Investigational Dermatology

Dermatology

2015

English

MA05.01 E6508: Phase II Study of Immunotherapy With Tecemotide and Bevacizumab After Chemoradiation in Unresectable Stage III NS-NSCLC

Journal of Thoracic Oncology

English

P2.01-113 Prognostic Roles of Neoadjuvant and Adjuvant Chemotherapy for Treating Patients With Operable Stage III-N2 Non-Small Cell Lung Cancer (NSCLC)

Journal of Thoracic Oncology

English

Amanote Research

Discover open access scientific publications

Search, annotate, share and cite publications

Publications by S. Maclachlan

P2.01-58 Demographics, Clinical Characteristics and Treatment Sequencing in Stage III Unresectable NSCLC Patients: A Cancerlinq Cohort

Related publications

P1.15-27 Patient Characteristics, Treatment Patterns and Survival for Unresectable Stage III NSCLC in Ontario, Canada

P2.01-91 Treatment Patterns in Patients With Stage IIIB-IV NSCLC in Clinical Practice: Retrospective Analysis of a UK Trust Database

P1.01-88 Osimertinib Maintenance After Definitive Chemoradiation in Patients With Unresectable EGFRm-Positive Stage III NSCLC (LAURA)

MA05.02 PACIFIC Subgroup Analysis: Pneumonitis in Stage III, Unresectable NSCLC Patients Treated With Durvalumab vs. Placebo After CRT

OA01.07 Updated Results of a Phase II Trial of Concurrent Chemoradiation With Consolidation Pembrolizumab in Patients With Unresectable Stage III NSCLC

P1.17-04 Curative Intent Treatment for Stage III NSCLC in England

Demographics, Clinical Disease Characteristics, and Quality of Life in a Large Cohort of Psoriasis Patients With and Without Psoriatic Arthritis

MA05.01 E6508: Phase II Study of Immunotherapy With Tecemotide and Bevacizumab After Chemoradiation in Unresectable Stage III NS-NSCLC

P2.01-113 Prognostic Roles of Neoadjuvant and Adjuvant Chemotherapy for Treating Patients With Operable Stage III-N2 Non-Small Cell Lung Cancer (NSCLC)